A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with Stage IIIB or IV metastatic breast cancer

Bates M, Lieu D, Zagari M, Spiers A, Williamson T.

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
9182022

Indexing Status
Subject indexing assigned by NLM

MeSH
Antibiotics, Antineoplastic /adverse effects; Antineoplastic Combined Chemotherapy Protocols /adverse effects; Breast Neoplasms /drug therapy /economics /pathology; Cost-Benefit Analysis; Cyclophosphamide /adverse effects; Decision Support Techniques; Doxorubicin /adverse effects; Economics, Pharmaceutical; Female; Fluorouracil /adverse effects; Health Care Costs; Heart Diseases /chemically induced /economics /prevention & control; Humans; Models, Economic; Neoplasm Staging; Randomized Controlled Trials as Topic; Razoxane /economics /therapeutic use; Sensitivity and Specificity; Value of Life

AccessionNumber
21997008174

Date bibliographic record published
27/11/1999